-
Mashup Score: 0‘Rife with irregularities’: Congressional investigation reveals FDA’s approval of Aduhelm marked by secret discussions, breaches of protocol - 1 year(s) ago
The FDA approval of Aduhelm included dozens of undisclosed calls and emails with Biogen and an “inappropriate” level of coordination with the company, investigators found.
Source: STATCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Seeking maximum profits, Biogen set an 'unjustifiably high price' for Alzheimer's treatment, investigation finds - 1 year(s) ago
The downfall of Aduhelm is largely the story of Biogen choosing to maximize its potential profits at the expense of patients and taxpayers, investigators found.
Source: STATCategories: General Medicine News, Latest HeadlinesTweet-
Biogen set an “unjustifiably high price” even though it knew charging so much for #Aduhelm would create a burden for Medicare, increase patients’ out-of-pocket costs, and lead to a backlash among physicians, according to congressional investigation. Read: https://t.co/Gy91PfrEgw https://t.co/eVtzzZU2SH
-
-
Mashup Score: 3
A new congressional report criticized the FDA and the drug maker, Biogen over the approval of an Alzheimer’s drug.
Source: Psychiatrist.comCategories: Latest Headlines, PsychiatryTweet-
𝑱𝑼𝑺𝑻 𝑰𝑵: New congressional report criticizes FDA and Biogen for the accelerated approval process of #Alzheimers Drug, #Aduhelm. It asks for substantial changes to the process. https://t.co/NWe5XdttjK
-
-
Mashup Score: 7Seeking maximum profits, Biogen set an 'unjustifiably high price' for Alzheimer's treatment, investigation finds - 1 year(s) ago
The downfall of Aduhelm is largely the story of Biogen choosing to maximize its potential profits at the expense of patients and taxpayers, investigators found.
Source: STATCategories: General Medicine News, Latest HeadlinesTweet-
THE ADUHELM FILES Internal documents reveal that #Biogen knew the risks of setting a high price for #Aduhelm but chose to push the envelope in hopes of creating the best-selling product in #pharma history. Read: https://t.co/ANdOSQ7tj6
-
-
Mashup Score: 4‘Rife with irregularities’: Congressional investigation reveals FDA’s approval of Aduhelm marked by secret discussions, breaches of protocol - 1 year(s) ago
The FDA approval of Aduhelm included dozens of undisclosed calls and emails with Biogen and an “inappropriate” level of coordination with the company, investigators found.
Source: STATCategories: General Medicine News, Latest HeadlinesTweet-
‘Rife with irregularities’: Congressional investigation reveals FDA’s approval of #Aduhelm marked by secret discussions, breaches of protocol https://t.co/aallPqtdlG
-
-
Mashup Score: 0Ahead of lecanemab decision, Alzheimer's groups petition CMS to reverse coverage policy - 1 year(s) ago
Aduhelm’s successor is now weeks away from its PDUFA date — and several advocacy groups are arguing for the reversal of a controversial CMS policy. The groups, including the Azheimer’s Association and a number of doctors and medical professionals, are advocating for CMS to reconsider its January announcement that restricts
Source: Endpoints NewsCategories: Hem/Oncs, Latest HeadlinesTweet-
@pash22 @LonSchneiderMD @nvillain_alz @MadhavThambiset @seb_walsh @AlbertoEspay @ProfRobHoward @PhilAlz @ayton_scott @AE_MD @reshmagar @gregggonsalves @MemoryDoc @jasonkarlawish @KarlHerrup @GiovanniFrisoni @macesari @geoperry @samgandy @Gill_Livingston @Kariem_Ezzat @andrea_sturchio @AndaloussiLab @rkhamsi @r_merrick @DrLiHueiTsai @adamfeuerstein @Jasonmmast @damiangarde @lauriemcginley2 @grace_huckins @aylinsdincer @PamBelluck @schrag_matthew @kathy_y_liu @dmrind @biogen @EisaiUS @naomikresge @DrMariaALZ @alzassociation @US_FDA @CMSGov @rdotinga @Medscape @drjohnm @Newsweek @95gunn This just in (yesterday actually). They haven’t given up, though #Aduhelm still looks like a stop, and you’ll get run over if you stand in the way of lecanemab. https://t.co/EncJpsYkrp
-
-
Mashup Score: 1
Biogen named Christopher Viehbacher, who formerly ran the French drug giant Sanofi, as its new CEO on Thursday.
Source: STATCategories: General Medicine News, Latest HeadlinesTweet-
#Biogen named Christopher Viehbacher as its new CEO on Thursday, opening a new chapter for one of the first and most successful biotechnology firms but one that has struggled since the disastrous launch of the #Alzheimers disease drug #Aduhelm. https://t.co/B4ovAWwWDq
-
-
Mashup Score: 0Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease—Estimating the True Value - 2 year(s) ago
To the Editor Alzheimer disease (AD) can be clinically devastating and costly, given its potential to profoundly impair quality of life and activities of daily living. Ross et al1 sought to evaluate cost-effectiveness of controversial novel antiamyloid monoclonal antibodies aducanumab and donanemab,…
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet-
In today's @JAMANeuro, @amarkelkar & I question the appropriateness & utility of cost-effectiveness analyses & estimating cost-effective prices for drugs that have yet to demonstrate clinical effectiveness, in the context of aducanumab & donanemab https://t.co/kMlNmHWc2V #aduhelm https://t.co/EIqEF3ZBJE
-
-
Mashup Score: 0
Medicare Part B beneficiaries’ premiums will be lowered in 2023 to compensate for lower-than-expected spending on Biogen’s Alzheimer’s disease drug Aduhelm, HHS Secretary Xavier Becerra announced F | While a mid-year redetermination was deemed unfeasible, HHS Secretary Xavier Becerra said Medicare’s Aduhelm cost savings would be passed on to enrollees via lower rates in 2023.
Source: Fierce HealthcareCategories: General Medicine News, Latest HeadlinesTweet-
#Aduhelm price cut, limited coverage leads @CMSGov to lower Medicare premiums in 2023 https://t.co/muiZBSfpz8
-
-
Mashup Score: 0
Medicare Part B beneficiaries’ premiums will be lowered in 2023 to compensate for lower-than-expected spending on Biogen’s Alzheimer’s disease drug Aduhelm, HHS Secretary Xavier Becerra announced F | While a mid-year redetermination was deemed unfeasible, HHS Secretary Xavier Becerra said Medicare’s Aduhelm cost savings would be passed on to enrollees via lower rates in 2023.
Source: Fierce HealthcareCategories: Future of Medicine, Latest HeadlinesTweet-
#Aduhelm price cut, limited coverage leads @CMSGov to lower Medicare premiums in 2023 https://t.co/Y3WmsnbyRB
-
Among the documents investigators unearthed in their 18-month investigation into the #FDA's approval of #Aduhelm are an internal review by the FDA of the drug's approval process that has not previously been made public. Read more: https://t.co/aEvd1swq8p https://t.co/xBwWcqxPVV